rtaker
Posted - 20 hours ago
$NUVB “Volume Precedes Price”?
rtaker
Posted - 2 days ago
$NUVB What’s with the 4.5M traded today!!!
Biotech2424
Posted - 1 week ago
Tang capital just bought 1.3 million more shares in Coherus. He got in Monopar recently and stock went up 400%. I’d imagine Tang will build this position from 2.3 million shares to 9.9% ownership 11 million shares. He is an expert in buying good science and value at excellent prices. And Coherus is right in his crosshairs with 2 oncology drugs set to generate $350 million next year. Trading at significant discount to 3.5x forward sales average biotech market caps avg.
https://hedgefollow.com/funds/Tang+Capital+Management
$CHRS $NUVB $VNDA $RCKT
PortPfohlio
Posted - 1 week ago
$NUVB added a little more today.
PortPfohlio
Posted - 1 week ago
$NUVB added a little more today
Biotech2424
Posted - 1 week ago
$CHRS Shorts barely moving stock anymore. Very Bullish on Coherus Short Interest 31,511,462 shares - source: NASDAQ Short Interest Ratio 7.42 Days to Cover Short Interest % Float 30.50 % - source: NASDAQ (short interest), Capital IQ (float) $VINC $NUVB
Big_Dzick
Posted - 2 weeks ago
$NUVB Big bet baby. Never sell
GarrettSquires
Posted - 2 weeks ago
$NUVB Bought in for earnings play. Set stop loss 10% otm. Don’t rarely ever speculate as I mostly buy blue chips but this one caught my eye. Made 10% on SONY today now moving it over here.
Big_Dzick
Posted - 2 weeks ago
$NUVB Hope 3 bucks next week baby
rtaker
Posted - 2 weeks ago
$NUVB Well kept secret for sure
rtaker
Posted - 2 weeks ago
$NUVB Been scouring their site and X but don’t see any news. Maybe we hear something PM.
Crackers20
Posted - 2 weeks ago
$NUVB what is with all the after hours trading
IN0V8
Posted - 2 weeks ago
$NUVB Opportunity RBC raises target price to $6 from $5
shukra_123
Posted - 2 weeks ago
$nuvb Submitted New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in October for the treatment of patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), positioning Company to commercialize taletrectinib, if approved, as early as mid-2025
ChessGM
Posted - 3 weeks ago
$NUVB Heads up alert! Only one day until Upcoming Earnings on Monday, 11/4/2024 Neutral (5.5) In evaluating Nuvation Bio Inc. ($NUVB), it is clear that the company is positioned within a dynamic sector characterized by significant investor interest, particularly from hedge funds. The stock has recently garnered attention as its insider ownership has increased, notably with Robert Mashal topping up his holding by $220k, indicating a strong internal belief in the company’s future prospects. Despite this positive sentiment, the company faces challenges, especially concerning its operations in China, where evolving legal uncertainties could impact its business strategy. Financially, Nuvation Bio's P/E ratio remains relatively high compared to industry peers, which may suggest overvaluation or anticipated growth. The company also needs to demonstrate tangible results in terms of earnings per share (EPS) growth and revenue forecasts if it wants to sustain investor confidence. Moreover, Nuvation Bio is part of a larger trend where small-cap biotech stocks are receiving increased attention, but this also means it faces stiff competition from other promising stocks in the same category. The recent appointment of Philippe Sauvage as Chief Financial Officer adds a seasoned perspective to their financial strategy, which could be a pivotal move to navigate through the current challenges. Overall, the mixed indicators from the market, combined with internal developments and external risks, suggest a nuanced outlook. --- Looking forward to the upcoming earnings report, analysts are cautiously optimistic. Historical performance has shown volatility in earnings, but consensus estimates suggest a modest EPS growth of approximately 5% year-over-year. Analysts will be closely watching revenue forecasts, which are projected to stabilize as the company enhances its product pipeline and expands market presence. The market's reaction to the earnings report will likely hinge on actual performance versus these estimates, especially given the recent focus on operational risks in China. The anticipation surrounding the earnings release could lead to increased volatility in Nuvation Bio's stock price, particularly if results deviate significantly from analyst expectations. - Funds were net sellers of $NUVB during the previous reporting quarter. - Top 1 funds with large holdings in $NUVB: * Acuitas Investments LLC $1MM. CGMRank: 58% - Last 10 days performance: -8% - Last 30 days performance: 0% - Last 90 days performance: -34% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.
Crackers115
Posted - 10/31/24
$NUVB can any find the earning report
PortPfohlio
Posted - 10/30/24
$NUVB Has anyone been able to view their website today? I just opened a small position and wanted to read up on them. Strange the stock is doing well today and the site seems to be down. Maybe a website update in process or maybe just me having issues.
arbwatson
Posted - 10/30/24
$NUVB Decent volume on this stock today. Key catalyst "Robust cash balance of $577 million and positive pivotal data from TRUST-I & TRUST-II studies of taletrectinib position Nuvation Bio to potentially become a commercial stage organization in 2025"
blood58870
Posted - 1 month ago
$NUVB managed to buy in at 2.00,gl if u play,looks good in the 2 dollar range
Northeast14
Posted - 1 month ago
$NUVB take a look at $GENFF under the radar and under valued
G101SPM
Posted - 1 month ago
$NUVB $2.28 ask. BUY/ADD TO LONG POSITION. DAC (2) $2.715. EXIT $7.00 in near term as first tier. BRIEF: *See prior post. OVERVIEW: Nuvation Bio plans to submit a New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2024. ^ Tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor (TKI)-naïve and 56% of those who were TKI-pretreated in the study ^ Taletrectinib demonstrated durable responses and prolonged progression-free survival (PFS) with long-term follow up; median duration of response (DOR) and median PFS in TKI-naïve patients were 44 months and 46 months, respectively ^Taletrectinib demonstrated a favorable safety and tolerability profile, including low incidence of neurologic treatment-emergent adverse events (TEAEs) and low rate of treatment discontinuation. * Click SEARCH icon on our landing page.
